洁特生物公告，2025年第一季度预计实现营业收入1.23亿元，同比增加25.16%。预计实现归属于母公司 所有者的净利润1400万元，同比增加71.18%。预计实现归属于母公司所有者的扣除非经常性损益的净 利润1350万元，同比增加218.52%。公司充分发挥自身在研发创新、生产工艺、精细化管理等方面的优 势，以市场为导向，依托客户需求，持续提升产品性能和产品竞争力，全力拓展市场份额。 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 经中国证券监督管理委员会《关于同意广州洁特生物过滤股份有限公司向不特定对象发行可转换公司债 券注册的批复》（证监许可〔2022〕432号）同意注册，公司向不特定对象共计发行440.00万张可转 债，每张面值为人民币100元，按面值发行。本次发行的募集资金总额为44,000.00万元，期限为自发行 之日起六年，即2022年6月28日至2028年6月27日。 证券代码：688026 证券简称：洁特生物 公告编号：2025-008 转债代码：118010 转债简称：洁特转债 广州洁特生物过滤股份有限公司 关于"洁特转债"预计满足转股价格修正条件的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 2025年3月21日至2025年4月3日，广州洁特生物过滤股份有限公司股票已有10个交易日的收盘价低于 当期转股价格的85%，预计触发转股价格向下修正条件。若未来触发转股价格向下修正条款，公司董事 会将召开会议决定是否行使"洁特转债"转股价格的向下修正权利，并 ...

Core Viewpoint - The company announces that its convertible bond, "洁特转债," is expected to trigger conditions for a downward adjustment of the conversion price due to the stock price being below 85% of the current conversion price for 10 trading days [1][2]. Group 1: Convertible Bond Details - The convertible bond code is 118010, and it is named "洁特转债" [1]. - The initial conversion price was set at 48.23 yuan per share, which was adjusted to 48.09 yuan on June 6, 2023, and further adjusted to 48.02 yuan on July 4, 2024 [2][3]. - The bond was issued in a total of 4.4 million units, with a face value of 100 yuan each, raising a total of 440 million yuan [2]. Group 2: Conversion Price Adjustment Conditions - The conversion price can be adjusted downward if the stock price is below 85% of the current conversion price for at least 15 out of 30 consecutive trading days [4]. - The period for potential triggering of the conversion price adjustment starts from March 21, 2025 [4]. - If the conditions are met, the board will decide whether to exercise the right to adjust the conversion price and will disclose this information in a timely manner [1][4].

| 证券代码：688026 | 证券简称：洁特生物 公告编号：2025-008 | | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | 广州洁特生物过滤股份有限公司 关于"洁特转债"预计满足转股价格修正条件的 提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 2025 年 3 月 21 日至 2025 年 4 月 3 日，广州洁特生物过滤股份有限公司 股票已有 10 个交易日的收盘价低于当期转股价格的 85%，预计触发转股价格向 下修正条件。若未来触发转股价格向下修正条款，公司董事会将召开会议决定是 否行使"洁特转债"转股价格的向下修正权利，并及时履行信息披露义务。 根据《上海证券交易所上市公司自律监管指引第 12 号——可转换公司债券》 的有关规定，广州洁特生物过滤股份有限公司（以下简称"公司"）可能触发可 转换公司债券（以下简称"可转债"）转股价格向下修正条件的相关情况公告如 下： 一、可转债发行上市情况 经中国证券监督管理委员会《关于同意广州洁特生物过滤股份有 ...

| 证券代码：688026 | 证券简称：洁特生物 公告编号：2025-007 | | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | 广州洁特生物过滤股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本季度转股情况：公司向不特定对象发行可转换公司债券证券"洁特转 债"自 2023 年 1 月 4 日起可转换为公司股份。自 2025 年 1 月 1 日至 2025 年 3 月 31 日期间，"洁特转债"共有人民币 0 元已转换为公司股票，转股数量为 0 股，占"洁特转债"转股前公司已发行股份总额的 0%。 ● 累计转股情况：截至 2025 年 3 月 31 日，"洁特转债"累计有人民币 3,000 元已转换为公司股票，转股数量为 60 股，占"洁特转债"转股前公司已发行股 份总额的 0.00004%。 ● 未转股可转债情况：截至 2025 年 3 月 31 日，"洁特转债"尚未转股的 可转债金额为人民币 439,997,000 元 ...

Group 1 - The company announced that the funds amounting to 11,473,149.78 yuan in its bank account have been unfrozen [1][2] - The funds were previously frozen due to a lawsuit filed by Shenzhen Hesheng Medical Technology Co., Ltd. regarding a mold procurement contract dispute [1] - The company has applied to the court to replace the frozen funds with other bank time deposits to minimize the impact of the lawsuit [1] Group 2 - Following the unfreezing, the company's bank account no longer has any frozen funds [2] - The lawsuit regarding the mold procurement contract is still under review by the Huangpu District People's Court and has not yet concluded [1]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州洁特生物过滤股份有限公司（以下简称"公司"）于近日获悉，本公司 银行基本账户内资金 11,473,149.78 元已解除冻结，现将有关情况公告如下： 一、银行账户部分资金被冻结的基本情况 公司于 2024 年 10 月 15 日披露了《关于公司银行账户部分资金被冻结的公 告》（公告编号：2024-069），由于深圳市合盛医疗科技有限公司（以下简称"合 盛医疗"）以模具采购合同纠纷为由起诉本公司，合盛医疗向广州市黄埔区人民 法院（以下简称"黄埔区人民法院"）申请财产保全，黄埔区人民法院据此冻结公 司账户中部分资金 11,473,149.78 元。 二、资金解除冻结的情况 公司与合盛医疗模具采购合同纠纷一案正在黄埔区人民法院审理，尚未结 案，鉴于被冻结账户为本公司银行基本账户，为将本次诉讼对本公司的影响降至 最低，经向相关人民法院申请，本公司使用公司名下其他银行的定期存单进行冻 结资金置换，本公司银行基本账户内原被冻结的资金已解除冻结，恢复正常使用。 本次解除冻结的账户情况如 ...

Core Viewpoint - Jiet Bio (688026) reported a revenue of 557 million yuan for 2024, representing a year-on-year growth of 20.28%, and a net profit of 73.81 million yuan, with a significant increase of 112.18% [1] Group 1: Financial Performance - The company's revenue for 2024 reached 557 million yuan, marking a 20.28% increase compared to the previous year [1] - Net profit for the same period was 73.81 million yuan, reflecting a substantial growth of 112.18% year-on-year [1] - Basic earnings per share stood at 0.53 yuan [1] Group 2: Market and Industry Trends - The domestic substitution policy has reduced the dependency on imported life science research tools, benefiting the company as a national-level specialized and innovative "little giant" enterprise [1] - Emerging technologies such as cell therapy and gene editing are driving the demand for high-end consumables [1] - The expansion of innovative drug companies and the increase in high-value orders from industrial clients are contributing to the company's growth [1]

Financial Performance - The company achieved total revenue of RMB 55,700.74 million in 2024, representing a year-on-year increase of 20.28%[4] - Operating profit reached RMB 9,733.00 million, up 146.76% compared to the previous year[4] - Net profit attributable to the parent company was RMB 7,381.42 million, reflecting a growth of 112.18% year-on-year[4] - The basic earnings per share increased to RMB 0.53, a rise of 112.00% from the previous year[4] Asset Management - The company's total assets at the end of 2024 were RMB 170,580.67 million, a 4.90% increase from the beginning of the period[4] Profitability - The gross profit margin improved by 10.1 percentage points to 40.7% due to cost optimization and increased sales volume[11] Product Development - The company developed several new products, including storage bags and cell culture bags, enhancing its product portfolio[9] Brand Promotion - The company participated in over 30 domestic and international life science and biotechnology exhibitions, boosting brand exposure[10] - The company plans to continue expanding its international brand promotion in regions such as Europe, the Middle East, and Southeast Asia[11] Market Environment - The company is benefiting from favorable policies in the domestic market, particularly in the life sciences sector, which is experiencing a recovery[9]

Financial Projections - The company expects to achieve an annual revenue of 560 million yuan in 2024, an increase of 96.9 million yuan, representing a year-on-year growth of 20.92%[3] - The projected net profit attributable to the parent company for 2024 is 70 million yuan, an increase of 35.2 million yuan, reflecting a year-on-year growth of 101.22%[3] - The net profit attributable to the parent company after deducting non-recurring gains and losses is expected to be 63 million yuan, an increase of 31.2 million yuan, with a year-on-year growth of 98.21%[3] Cost Management and Profitability - The company has implemented cost control measures for raw materials and optimized internal management to reduce production costs, resulting in a significant increase in gross profit margin[6] Market Strategy - The company is focusing on expanding its product range and series while maintaining stable product prices in both domestic and international markets[6] - The company is actively developing new customers and maintaining relationships with existing clients through the establishment of its own brand sales team overseas[6] - The performance of the company's main business has been strong, with a continuous increase in market share contributing to the revenue growth[6] Financial Caution - The financial data provided is preliminary and has not been audited by registered accountants, and investors are advised to be cautious[7][8]